ROCKVILLE, Md., April 18,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:
RGNX) today announced it will present in a fireside chat at
Chardan's 7th Annual Genetic Medicines and Cell Therapy
Manufacturing Summit on Tuesday, April 25,
2023 at 9:30 a.m. ET. The
conference will be held in a virtual meeting format.
A live webcast of the fireside chat can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available in the Investors
section of REGENXBIO's website for approximately 30 days following
the fireside chat.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-chardans-7th-annual-genetic-medicines-and-cell-therapy-manufacturing-summit-301799830.html
SOURCE REGENXBIO Inc.